Airway Therapeutics

Atlanta-area late-stage clinical biopharmaceutical company developing zelpultide alfa (recombinant human surfactant protein D) for bronchopulmonary dysplasia and other respiratory/inflammatory diseases; closed a $50 million equity round (including a $24M Series E-2) in 2026.